ArticleCommunications biology2025
Ovalbumin-induced asthma leads to bone loss with Piezo channel suppression in mice.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fluticasone Propionate/Anti-IgE Combination Preserves Bone Mechanical and Mineral Integrity Better than Monotherapies or Anti-TNF-α in Mice with Ovalbumin-Induced Allergic Airway Inflammation.International journal of molecular sciences · 2026Article
- Bone health in asthma: a twofold effect of disease and pharmacotherapy.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The impact of allergic diseases on bone loss remains unclear because it is considered to result from the use of corticosteroids to ameliorate allergic inflammation. To explore the effects of allergic diseases on bone metabolism, we investigated long bones in ovalbumin (OVA)-induced asthmatic mice. Compared with that of vehicle-treated controls, the bone mass of OVA-induced asthmatic mice was lower. We found fewer mature osteoblasts on the surfaces of the cortical and trabecular bones of allergen-sensitized mice than in those of vehicle-treated mice. Piezo1 and Piezo2 were located in mature osteoblasts, and their expression levels decrease during osteocytogenesis. Compared with that in non-asthmatic mice, the expression levels of both Piezo1 and Piezo2 were suppressed in asthmatic mice. The Piezo1 agonist reversed OVA-induced bone loss, with increased osteogenesis and type I collagen (Col1) expression. Furthermore, compared with control mice, Piezo2 heterozygous deletion mice with OVA presented a decreased bone volume. Our data suggest that asthma could induce osteopenia and that Piezo channel modulation could be a possible way to prevent bone loss induced by allergic asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.